In the early 1980s,
Ajay Piramal took over the reins of Piramal Group. In 1984, the group acquired
Gujarat Glass Limited (later renamed as Piramal Glass), a manufacturer of glass packaging for
pharmaceutical and
cosmetic products. In 1988, the group bought Nicholas Laboratories, which later flourished and by 2010 reached the highest valuation in the
pharmaceutical industry. Over the decade, the company acquired many business units to strengthen their presence. In November 1993, Swiss drug multinational Hoffmann-La Roche sold its Indian subsidiary, Roche Products (India) Ltd to Piramal Enterprises, including its assets like the Vitamin-A producing Fine Chemicals Plant in Balkum, Thane. Roche Products was later renamed Piramal Healthcare Ltd. In 1999, Piramal Glass acquired Ceylon Glass Company Limited, Sri Lanka. In 2006, the company bought
Pfizer’s UK manufacturing facility in
Morpeth. The company also formed the Piramal Foundation, a philanthropic arm of the group. In 2007, it underwent a deal with
Merck Pharmaceuticals for development and discovery of new drugs. In 2008, it signed a second drug development deal with
Eli Lilly and Company. The company Nicholas Laboratories was renamed to Piramal Healthcare Ltd. In 2010, Piramal Healthcare sold its domestic formulations business to Abbott for $3.72 billion (about 18,000 crore). It was considered to the "most expensive pharma deal ever" by
Forbes India. Piramal Healthcare then sold its diagnostics chain Piramal Diagnostic Services to
SRL for 600 crore. In the same year, the group formed its own real estate entity, Piramal Realty. 2011 saw
Fortune 500 ranking Piramal Healthcare in the top-50 largest corporations across India. UN Conference on Trade and Development’s World Investment Report 2011 ranked Piramal Healthcare as No. 5 in the top 10 pharmaceutical contract manufacturers worldwide. In 2011–12, Piramal bought 11% in Vodafone Essar. In 2014, it sold its 11% Stake in
Vodafone India to Prime Metals, an indirect subsidiary of
Vodafone Group. In 2012, Piramal Healthcare was renamed to
Piramal Enterprises Ltd. BST-CarGel, Piramal's innovative bio-orthopaedic product for cartilage repair, received European CE mark approval. Piramal's Decision Resources Group acquired Abacus International, a UK based company. Piramal Enterprises acquired the brand
Caladryl in India. Caladryl is an
anti-pruritic solution known for dermatosis application for minor skin irritations and itching. This acquisition enabled Piramal Enterprises to widen its consumer products portfolio in the skin care segment. Piramal Imaging entered into a Strategic Partnership and Exclusive Licensing Agreement with Ci-Co Healthcare for Commercialization of
florbetaben F18. European Union’s CHMP recommends EU approval of Piramal Imaging’s radiopharmaceutical NeuraCeq (florbetaben 18F). In December 2020, Piramal Glass was sold to
The Blackstone Group for 1 billion. ==Group companies==